Rapport Therapeutics Secures $328M China Deal for Seizure Drug RAP-219
Event summary
- Rapport Therapeutics grants Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China for $20M upfront and up to $308M in milestones.
- RAP-219, a TARPγ8-specific AMPA receptor modulator, showed promising Phase 2a results in drug-resistant focal onset seizures.
- Tenacia will add Phase 3 clinical trial sites in China, accelerating RAP-219's global development.
- Rapport retains rights to RAP-219 in all other territories and will receive mid-single-digit to mid-teens tiered royalties on net sales in Greater China.
The big picture
This deal underscores the growing trend of Western biotechs partnering with Chinese firms to accelerate drug development in underserved neurological markets. The $328M potential deal size highlights the strategic value of RAP-219, particularly as Tenacia leverages its CNS expertise to expand access in Greater China. The collaboration also reflects the increasing financial discipline among biotechs, using licensing agreements to extend runway without diluting equity.
What we're watching
- Clinical Execution
- Whether Tenacia can successfully integrate RAP-219 into its Phase 3 trials in China and meet regulatory timelines.
- Market Expansion
- How the Greater China deal positions RAP-219 for broader global commercialization beyond epilepsy into bipolar disorder and other indications.
- Financial Impact
- The pace at which Rapport Therapeutics can leverage this non-dilutive capital to advance its other precision neuroscience programs.
Related topics